Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
about
Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policiesPharmaceutical policies: effects of reference pricing, other pricing, and purchasing policiesThe new medicare drug benefit: formularies and their potential effects on access to medicationsThe experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine useChanges in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gapPotential Savings from an Evidence-Based Consumer-Oriented Public Education Campaign on Prescription DrugsConsistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization dataEffect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records.Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?Effects of prescription adaptation by pharmacists.Reference drug programs: effectiveness and policy implications.The impact of cost sharing on antidepressant use among older adults in British Columbia.Comparison of tiered formularies and reference pricing policies: a systematic review.Impact of drug cost sharing on service use and adverse clinical outcomes in elderly receiving antidepressants.Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarctionEffects of prescription coinsurance and income-based deductibles on net health plan spending for older users of inhaled medications.Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications.Rethinking prescribing in the United StatesEffectiveness, safety and cost of drug substitution in hypertensionPatient socioeconomic determinants of the choice of generic versus brand name drugs in the context of a reference price system: evidence from Belgian prescription dataPharmaceutical cost containment with reference-based pricing: time for refinementsEconomic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans.Impact of drug policy on regional trends in ezetimibe useA review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods.Factors that influence patient response to requests to change to a unified restrictive formularyPatient Barriers to Mammography Identified During a Reminder Program.Applying propensity score methods in medical research: pitfalls and prospects.Drug insurance utilization management policies and "reference pricing": an illustrated commentary on the article by Vittorio Maio and colleagues.Medicare Part D's effect on the under- and overuse of medications: a systematic review.Selecting the Acceptance Criteria of Medicines in the Reimbursement List of Public Health Insurance of Iran, Using the "Borda" Method: a Pilot StudyPatient, physician, pharmacy, and pharmacy benefit design factors related to generic medication useMeasuring prescribing improvements in pragmatic trials of educational tools for general practitioners.Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004The effect of evidence-based drug coverage policies on pharmaceutical r&d: a case study from british columbiaGaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach.Is there a relationship between patient beliefs or communication about generic drugs and medication utilization?Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations.Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study.Effect of a multimodal reminder program on repeat mammogram screeningThe effect of evidence-based drug coverage policies on pharmaceutical r&d: a case study from british columbia.
P2860
Q24193097-EAAF934D-9375-413E-AD76-294E6237C9FBQ24246148-3D275024-D4F8-41DC-BB2E-47BF5B466781Q24540426-96C45E93-DDDB-49EF-BE5D-37A24FDF1A99Q27007695-8186F195-146D-4C5F-9341-999975CDBE9CQ28476575-16747E14-39AF-474C-AF6E-224DF5DF0C2AQ29393270-29A2F4F2-FE74-49E6-A16C-58251E5B1DEAQ30925301-F2E8C1DA-3D45-450E-84FD-0B024119394EQ33659515-1EB97E25-54DC-4C21-A84C-14478481CAD9Q33664087-03D56868-CCCB-49C4-852A-45004460FD63Q33749038-714A4AE5-C1C1-4E30-A202-972B81335F8EQ33908085-5B8160FE-DE91-417C-BDAA-0BFFEE28A8DEQ33908092-2598502A-9A1E-49FB-97B7-DC459C3CC148Q33908282-D4610922-6964-4414-A487-AB51AB224BBCQ33942027-632405FA-6E7D-4F68-8365-199ABF6FBD42Q34001855-940345D5-F22D-4D0D-BED6-DA457A598F87Q34001878-6CFBA8B0-5BE9-4FF4-87B7-86A993FB67C2Q34001895-B3770B06-C95E-4FEF-8B69-623FB2CD0F51Q34091281-A375ADA9-AF7A-40E1-9C33-BC912B13A939Q34174844-C7CF209F-C999-4B51-AEDA-87CC5CE56FE5Q34199300-2046DA72-F023-40E2-AF38-F6D2F9668C65Q34288380-51F8257D-520E-4FB2-8DD6-26D56A73A4EDQ34335952-F203946E-0D65-4233-B589-86C24D98D830Q34462245-6AA0A541-EDAF-4660-822E-5DDF09F8DAA8Q34567560-CA8CE387-8967-4184-BEF2-D8F2A4EA9BD9Q34733804-C92707DE-BA83-490F-865A-CAF48550C905Q35051743-9D14C89E-BCD2-4AD9-9D25-E955E4D0621DQ35710639-3A97057E-65A3-411D-BA88-2D21D0D7AFF3Q36078789-E2F91315-9D8F-4B42-97BF-862950A4DDFEQ36105740-40E55FB2-94F7-4EAB-A188-CA58D5F5B227Q36358445-F486C60D-37F9-49D5-ACFF-F6725030977DQ36416773-178E8808-8613-435A-A951-874D28E6B9FAQ36447520-C3221D0F-9E78-40EB-98CD-CC3E8021D1D8Q36468237-8B0D89FE-AC0E-4FB1-84B6-A17CEBC5945DQ37103226-151863B8-19FB-4502-8582-ACFCFE1616C7Q37113241-EF441333-C59C-4A36-A5E8-F5B3036D1C3FQ37246833-08BC788B-87C7-445E-B244-60F0DB9489D3Q37261320-BCB98D75-DCA4-4CAC-B324-361EDCBC4D9BQ37352239-4B7AD181-18CB-4039-B474-1BC9E8CC38BBQ37370252-B9E30CDC-DB63-46E8-A55E-E6A683604FB8Q37420464-02B7A062-5994-4265-999B-868FDBB3303B
P2860
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
@ast
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
@en
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
@nl
type
label
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
@ast
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
@en
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
@nl
prefLabel
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
@ast
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
@en
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
@nl
P2093
P356
P1476
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
@en
P2093
Alexander M Walker
Malcolm Maclure
Robert J Glynn
Sebastian Schneeweiss
Stephen B Soumerai
P304
P356
10.1056/NEJMSA003087
P407
P577
2002-03-01T00:00:00Z